
Oncology
18 Oct 2025
ESMO 2025: DESTINY-Breast11 Trial Results Revealed
The DESTINY-Breast11 phase 3 trial presented at ESMO 2025 revealed that the anthracycline-free neoadjuvant T-DXd-THP regimen achieved a 67.3% pathologic complete response rate, outperforming standard chemotherapy while reducing severe side effects in patients with high-risk HER2-positive early breast cancer.
Latest Journals
All JournalsCongress Reviews
All Congress ReviewsLatest Infographics
All InfographicsLatest Podcasts
All Podcasts